How does pure heart rate lowering impact on cardiac tolerability?

European Heart Journal, Supplement

Volumn 8, Issue D, 2006, Pages

  Camm, A John ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cardiac electrophysiology; Cardiac tolerability; Heart rate; If inhibition; Ivabradine; Myocardial contractility; QT interval; Sinus bradycardia

Indexed keywords

AMLODIPINE; ANTIANGINA PECTORIS AGENT; ATENOLOL; IVABRADINE;

ANGINA PECTORIS; ARTIFICIAL HEART PACEMAKER; BRADYCARDIA; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROPHYSIOLOGY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE PERFORMANCE; HEART MUSCLE CONTRACTILITY; HEART PROARRHYTHMIA; HEART RATE; HEART REPOLARIZATION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HUMAN; INOTROPISM; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; RETINA; REVIEW; SINUS BRADYCARDIA; SINUS NODE RECOVERY TIME; STABLE ANGINA PECTORIS; SUPRAVENTRICULAR PREMATURE BEAT; SUPRAVENTRICULAR TACHYCARDIA; VISUAL DISORDER;

EID: 33748805263     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sul019     Document Type: Review

References (25)

1. Saha M, Marber MS. If at first you don't succeed try ... a new target in the treatment of angina. Eur Heart J 2005;26:2482-2483.
2. Summary of Product Characteristics. Procoralan. European Medicines Agency. http://www.emeaeuint/humandocs/humans/epar/procoralan/procoralan.htm (2005).
3. Brown HF, DiFrancesco D, Noble SJ. How does adrenaline accelerate the heart? Nature 1979;280:235-236.
4. Baruscotti M, Bucchi A, DiFrancesco D. Physiology and pharmacology of the cardiac pacemaker ('funny') current. Pharmacol Ther 2005;107:59-79.
5. Glasser SP, Michie DD, Thadani U, Baiker WM. Effects of zatebradine (ULFS 49 CL), a sinus node inhibitor, on heart rate and exercise duration in chronic stable angina pectoris. Zatebradine Investigators. Am J Cardiol 1997;79:1401-1405.
6. Bois P, Bescond J, Renaudon B, Lenfant J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 1996;118:1051-1057.
7. Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003;107:817-823.
8. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529-2536.
9. Ruzyllo W, Ford IF, Tendera MT, Fox KF. Antianginal and antiischemic effects of the If current inhibitor compared to amlodipine as monotherapies in patients with chronic stable angina. (Abstract). Randomised, controlled, double-blind trial. Eur Heart J 2004;25(Suppl.):878.
10. Lenzen MJ, Boersma E, Bertrand ME, Maier W, Moris C, Piscione F, Sechtem U, Stahle P, Widimsky P, de Jaegere P, Scholte op, Reimer WJ, Mercado N, Wijns W, European Society of Cardiology. Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. Eur Heart J 2005;26:1169-1179. Published online ahead of print March 31, 2005.
11. Bucchi A, Baruscotti M, DiFrancesco D. Current-dependent block of rabbit sino-atrial node I(f) channels by ivabradine. J Gen Physiol 2002;120:1-13.
12. DiFrancesco D, Camm AJ. Heart rate lowering by specific and selective If current inhibition with ivabradine. A new therapeutic perspective in cardiovascular disease. Drugs 2004;64:1757-1765.
13. Robinson RB, Siegelbaum SA. Hyperpolarization-activated cation currents: from molecules to physiological function. Annu Rev Physiol 2003;65:453-480.
14. Camm AJ, Lau CP. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D 2003;4:83-89.
15. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf 2001;24:323-351.
16. Savelieva I, Camm AJ. Absence of direct effects of the If current blocker ivabradine on ventricular repolarization: analysis based on a population heart rate correction formula. (Abstract). J Am Coll Cardiol 2005;45:95A.
17. Savelieva I, Jones S, Dougal K, Malik M, Camm AJ. Noninvasive electrophysiological study of ivabradine (NESI) in patients with dual chamber pacemakers: effects on ventricular repolarization. (Abstract). J Am Coll Cardiol 2006;47:27A.
18. Vilaine JP, Bidouard JP, Lesage L, Reure H, Peglion JL. Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs. J Cardiovasc Pharmacol 2003;42:688-696.
19. Simon L, Ghaleh B, Puybasset L, Giudicelli JF, Berdeaux A. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995;275:659-666.
20. Monnet X, Ghaleh B, Colin P, de Curzon OP, Giudicelli JF, Berdeaux A. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning. J Pharmacol Exp Ther 2001;299:1133-1139.
21. Monnet X, Colin P, Ghaleh B, Hittinger L, Giudicelli JF, Berdeaux A. Heart rate reduction during exercise-induced myocardial ischaemia and stunning. Eur Heart J 2004;25:579-586.
22. Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003;100:149-155.
23. Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F, Renet S, Lerebours G, Mahlberg-Gaudin F, Thuillez C. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004;109:1674-1679.
24. Jondeau G, Korewicki J, Vasiliauskas D. Effect of ivabradine in patients with left ventricular systolic dysfunction and coronary artery disease. (Abstract). Eur Heart J Suppl 2004;25:2637.
25. Fox K, Ferrari R, Tendera M, Steg PG, Ford I. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular dysfunction: the morBidity-mortality EvAlUation of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) Study. Am Heart J 2006, in press.